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ABSTRACT: While the central role of locus-specific acetylation of histone proteins in eukaryotic gene expression is well 
established, the availability of designer tools to regulate acetylation at particular nucleosome sites remains limited. Here, 
we develop a unique strategy to introduce acetylation by constructing a bifunctional molecule designated Bi-PIP. Bi-PIP 
has a P300/CBP-selective bromodomain inhibitor (Bi) as a P300/CBP recruiter and a pyrrole–imidazole polyamide (PIP) as 
a sequence-selective DNA binder. Biochemical assays verified that Bi-PIPs recruit P300 to the nucleosomes having their 
target DNA sequences and extensively accelerate acetylation. Bi-PIPs also activated transcription of genes that have corre-
sponding cognate DNA sequences inside living cells. Our results demonstrate that Bi-PIPs could act as a synthetic program-
mable histone code of acetylation, which emulates the bromodomain-mediated natural propagation system of histone acet-
ylation to activate gene expression in a sequence-selective manner. 
■ INTRODUCTION 
Posttranslational modifications (PTMs) on histone pro-
teins play significant roles in epigenetic regulation of eu-
karyotic chromatin. Acetylation of epsilon-amine on lysine 
residues is one of the major PTMs on histones, and is 
strongly correlated with transcriptional activation. The 
code governing histone acetylation is regulated by histone 
acetyltransferases (HATs) as writers and by histone 
deacetylases (HDACs) as erasers. Acetylated histones are 
known to operate via two mechanisms. One is to decrease 
the positive charge of histone proteins, resulting in weak-
ened interaction between histones and DNA, which in turn 
open up the chromatin structure.1 The second is mediated 
by bromodomain (BD)-containing proteins, which selec-
tively bind to acetylated lysine residues.2,3 
Although locus-specific (i.e., DNA sequence-specific) 
regulation of histone acetylation has been shown to be es-
sential in biological processes, techniques for controlling 
histone acetylation at any region of interest remain limited. 
Recently, programmable DNA-binding module proteins 
such as transcription activator-like effectors (TALEs) and 
clustered regularly interspaced short palindromic repeat 
(CRISPR)/Cas systems were fused to the catalytic domain 
of histone acetyltransferase P300 for sequence-selective 
histone acetylation.4 Although targeted acetylation was 
demonstrated using the dCas9–P300 Core fusion protein, 
the transfection-based system could limit their clinical ap-
plications. Moreover, such protein-based molecules are 
amenable to enzymatic degradation in the cellular envi-
ronment. In these contexts, the development of chemically 
synthesized sequence-selective molecules is a promising 
alternative for locus-specific acetylation of histones, avoid-
ing the need of transfection and enzymatic degradation. 
Pyrrole–imidazole polyamides (PIPs) are a class of syn-
thetic molecules that bind to DNA in a sequence-selective 
manner.5 In the anti-parallel hairpin structure, a pair of 
pyrrole and pyrrole (Py/Py) recognizes A•T or T•A base 
pair, while a pair of imidazole and pyrrole (Im/Py) does G
•C base pair.6 It is known that the aliphatic β-alanine can 
substitute and partake the selective binding functionality 
of the Py in the PIP chemical architecture.7 Also, β-alanine 
could confer the PIPs with better flexibility and improved 
binding affinity. By conjugating PIP with a HDAC inhibitor 
SAHA, our group previously developed a class of designer 
molecule called SAHA-PIP for sequence-selective histone 
acetylation.8 SAHA-PIPs with different sequence-specific-
ity activated silenced genes including pluripotency 
genes,9,10 germ cell-associated genes,11 retinal genes,12 neu-
ral genes,13 and key therapeutically important genes14 in hu-
man dermal fibroblasts. Despite the proclaimed potential 
of SAHA-PIPs as epigenetic drugs, the level of gene activa-
tion was still inconsistent. One reason for this observation 
could be the fact that induction of histone acetylation by 
inhibiting HDACs is an indirect outcome and acetylation 
will not occur if HATs are absent in the region. As an alter-
native approach, a P300 activator N-(4-chloro-3-trifluoro- 
  
Figure 1. Strategy of targeted histone acetylation utilizing the 
bromodomain (BD)-mediated propagation of acetylation. (a) 
Structure of P300/CBP coactivator proteins. NRID, nuclear re-
ceptor interacting domain; TAZ1, transcriptional adaptor zinc 
finger 1; KIX, KID-interacting; BD, bromodomain; RING, really 
interesting new gene; PHD, plant homeodomain; HAT, his-
tone acetyltransferase; ZZ, ZZ-type zinc finger; TAZ2, tran-
scriptional adaptor zinc finger 2; IBiD, interferon-binding do-
main. (b) BD-mediated propagation of histone acetylation by 
P300/CBP. Existing acetyl lysine (yellow) is recognized by BD 
of P300/CBP, and de novo acetyl modification (green) is intro-
duced by HAT domain. (c) Design of artificial epigenetic code 
of acetylation named ‘Bi-PIP’ (left) and model of targeted his-
tone acetylation by Bi-PIP (right). Bi mimics acetyl lysine to 
recruit P300/CBP through its BD. 
methyl-phenyl)-2-ethoxy-benzamide (CTB)15 was conju-
gated to PIPs.16 However, the mechanism by which CTB op-
erates is yet to be clarified and there is no clear evidence to 
substantiate the interaction of CTB with P300.17 Therefore, 
there is a need for (1) a more reliable and robust molecular 
design, and (2) proof-of-concept experiments of the molec-
ular mechanism, to achieve sequence-selective histone 
acetylation in a similar manner to that observed in natural 
cellular environment. 
Interestingly, HAT domain and BD sometimes appear in 
the same protein. In humans, GCN5 (KAT2A), PCAF 
(KAT2B), P300 (KAT3B), CBP (KAT3A), TAF1 (KAT4), and 
BRD4 contain both HAT and BD in their structures (Fig-
ure 1a).18–21 This is thought to contribute to the robust 
maintenance of highly acetylated chromatin; one acetyl 
mark causes acetylation of neighboring sites via BD-
mediated recruitment of these proteins (Figure 1b).18,22,23 
This natural system inspired us to develop a novel ap-
proach based on the BD-mediated acetylation to acetylate 
histones in targeted nucleosome. 
Small molecules targeting the BD-containing proteins 
have been identified and developed in recent years.24–28 
These BD inhibitors specifically bind to the pockets of BD 
to prevent binding with an acetylated lysine residue. 
Therefore, BD inhibitors could be used as a mimetic of 
acetylated lysine to probe BDs. 
We hypothesized that locus-specific acetylation by a 
HAT-BD protein such as P300 could be achieved when a 
BD inhibitor is localized to a specific DNA sequence (Fig-
ure 1c). Herein, we report the development of a novel mol-
ecule named ‘Bi-PIP’ by conjugating a BD inhibitor (Bi) and 
PIP. We demonstrate a proof-of-concept that Bi-PIP can 
enhance histone acetylation by P300 in a sequence-selec-
tive manner and clarify their mode of action. 
 
■ RESULTS 
Design and synthesis of Bi-PIP as a sequence-spe-
cific artificial histone code of acetylation. We selected 
the coactivator P300/CBP family of proteins as the target 
for the artificial histone code (Figure 1a). P300/CBP plays 
a central role in transcriptional activation in eukaryotic 
cells.29 Given that P300/CBP has both HAT and BD, BD-
mediated propagation of histone acetylation was proposed 
(Figure 1b).18 A P300/CBP-selective BD inhibitor (CBP30) 
having 5-isoxazolyl-benzimidazole was previously devel-
oped by Hay et al. (Supplementary Figure 1).25 X-ray crys-
tal structure analyses revealed that the 3,5-dimethylisoxa-
zole moiety in CBP30 enters the pocket in the BD of CBP 
and P300, mimicking acetylamide of epsilon-acetylated ly-
sine residue.25,30 The other two domains, terminal aryl 
group and morpholine moiety, are located outside of the 
pocket, suggesting that they could be sites for conjugation 
with PIPs (Supplementary Figure 1).30 For synthetic ac-
cessibility of building blocks, we chose one of the CBP30 
derivatives (1 in Figure 2, named ‘Bi’ in this study), which 
showed a moderate binding affinity to the BD of CBP (Fig-
ure 2, Supplementary Figure 2) and attempted to attach 
a linker domain on the methoxy group.25 A BD inhibitor 
unit (Bi Unit) with primary amine was then designed and 
synthesized (Supplementary Scheme 1). By coupling 
with PIPs, which has a carboxylic acid at the N-terminus, 
two conjugates, termed Bi-PIP1 (2) and Bi-PIP2 (4) target-
ing 5′–WWCWGWCW–3′ and 5′–WGCCGCCW–3′, respec-
tively, were synthesized (W = A or T, Figure 2). 
Bi-PIPs promote histone acetylation on nucleo-
somes that possess their target DNA sequences. To 
test sequence-selective histone acetylation by Bi-PIP, we 
sought to establish a biochemical assay by combining HAT 
reaction followed by immunoprecipitation using reconsti-
tuted nucleosomes reported previously22 and quantitative 
polymerase chain reaction (qPCR). We reconstituted mon-
onucleosomes using a salt-dialysis method31 from a histone 
octamer and DNA templates that each have a Widom 601 
nucleosome positioning sequence32 and five PIP-binding 
sequences: 5′–AACAGTCA–3′ for Bi- PIP1 and 5′–
AGCCGCCA–3′ for Bi-PIP2 (Figure 3a). Gel electrophore- 
  
Figure 2. Chemical structures of Bi (1), Bi-PIP1 conjugate (2), PIP1 monomer (3), Bi-PIP2 conjugate (4), and PIP2 monomer (5). 
sis confirmed that the majority of DNA templates were 
successfully formed on the nucleosome (Supplementary 
Figure 3). Two types of nucleosomes, one with five match 
sequences for Bi-PIP1 (Nuc1) and the second for Bi-PIP2 
(Nuc2), were mixed and incubated with recombinant hu-
man P300 (amino acid 965–1810) including the BD and 
HAT with or without Bi-PIP1. The reaction mixture was 
then immunoprecipitated using an antibody for pan-acet-
ylated H3 (acetylation at K9, K14, K18, K23, K27), followed 
by qPCR analysis to measure the amount of each nucleo-
some (Figure 3b). 
In the absence of the Bi-PIP, the level of acetylation of 
the nucleosomes got slightly increased only in the presence 
of 100 nM of P300. On the other hand, addition of 100 nM 
Bi-PIP1 induced intensive acetylation on its target Nuc1 but 
not on Nuc2 (Figure 3c). The increase in the level of acet-
ylation was dependent on the concentration of P300. Next, 
to clarify the importance of the Bi and PIP domains, each 
monomer molecule was tested in the assay. The PIP mon-
omer alone (3), Bi monomer alone (1), and even a mixture 
of them could not promote the acetylation (Figure 3d). 
The result clearly indicates that the Nuc1-selective acetyla-
tion by Bi-PIP1 was achieved by sequence-selective binding 
of the PIP domain to its target DNA sequence and P300 re-
cruitment mediated by a BD–Bi interaction (Figure 1c). To 
examine the programmability of Bi-PIP, we tested Bi-PIP2 
designed to target Nuc2. Bi-PIP2 caused selective acetyla-
tion of Nuc2, indicating that the target sequence of Bi-PIP 
is programmable (Figure 3e). 
Taken together, we established that HAT reaction fol-
lowed by in vitro ChIP-qPCR could be used to quantify the 
acetylation of individual nucleosomes, thereby demon-
strating a proof-of-concept of sequence-selective acetyla-
tion with Bi-PIP using the assay. 
Next, to investigate the effect of linker length of Bi-PIP, 
Bi-PIP1 with a shorter linker (Bi-PIP1-short, 6) and one 
with a longer linker (Bi-PIP1-long, 7) were synthesized 
(Supplementary Figure 4a) and compared with the orig-
inal Bi-PIP1 in the assay. Acetylation of Nuc1 was enhanced 
at a similar level in Bi-PIP1-short, Bi-PIP1, and Bi-PIP-long 
(Supplementary Figure 4b). The result suggests that all 
three Bi-PIPs have a sufficiently long and flexible linker for 
the effective acetylation of H3. Indeed, the N-terminal tail 
region of H3 is known to be located near the linker DNA,33 
where the binding sites for PIPs are located. 
To clarify the binding site(s) essential for the acetylation, 
we carried out studies using five additional templates that 
have a single binding site for Bi-PIP1 at different positions 
(Nuc3–7). Among the five nucleosomes, Nuc3, which has a 
binding site at the closest position to the nucleosome core 
particle, showed the highest level of acetylation (Supple-
mentary Figure 5). Thus, this is the most effective posi-
tion for the acetylation. However, to our surprise, the acet-
ylation level of Nuc3 was much lower than that of Nuc1 
(Supplementary Figure 5). Moreover, even the sum of 
acetylation levels of Nuc3–7 did not reach the value for 
Nuc1, suggesting the existence of synergistic effects of mul-
tiple P300s on a single nucleosome (Supplementary Fig-
ure 5). Although this phenomenon could be explained by 
  
Figure 3. Bi-PIPs promote histone acetylation on nucleosomes that possess their target DNA sequences. (a) Schematic of DNA 
templates used for the assay. Blue and red rectangles represent binding sites for Bi-PIP1 and Bi-PIP2, respectively. (b) Schematic 
of HAT reaction-in vitro ChIP-qPCR. (c) A HAT reaction-in vitro ChIP-qPCR was performed with a series of P300 concentration 
(0, 3, 10, 30, 100 nM) with or without 100 nM of Bi-PIP1. Positive control represents a nucleosome with synthetic acetylated histone 
H3 (K4ac, K9ac, K14ac, K18ac, K23ac). (d) A HAT reaction-in vitro ChIP-qPCR was performed with 10 nM of P300. Each compound 
was applied at a concentration of 100 nM. (e) A HAT reaction-in vitro ChIP-qPCR was performed Bi-PIP1 (100 nM) or Bi-PIP2 (100 
nM) with 10 nM of P300. 
 the previously reported intermolecular auto-acetylation of 
P300,34,35 further studies is required to investigate the 
mechanism in detail. 
Finally, histone acetylation with Bi-PIP was directly con-
firmed by mass spectrometry analysis. After HAT reaction, 
the histones were processed through propionylation of un-
modified lysine, tryptic digestion, and propionylation of 
terminal amine.36,37 The resulting peptides were analyzed 
by liquid chromatography–tandem mass spectrometry 
(LC-MS/MS). Consistent with the antibody-based assays 
shown above, an increase in the signal intensity was ob-
served for peptides containing acetyl lysine at the N-termi-
nal tail region of H3, such as H3K14ac, H3K18ac, H3K23ac, 
H3K27ac, and H3K36ac (Supplementary Figure 6a, 6c). 
It was also found that acetylation was promoted in the N-
terminal region of histone H4, including H4K5ac, H4K8ac, 
and H4K12ac (Supplementary Figure 6b, 6d). The acety-
lation at N-terminal tail region of H3 and H4 by P300 is 
consistent with previously reported results, where P300 
gets recruited to reconstituted chromatin by DNA-binding 
activator proteins.38 
Bi-PIPs epigenetically activate selective gene ex-
pression inside living cells. We then evaluated if Bi-PIPs 
could function in a cellular environment. As an initial ex-
periment, we performed a HAT reaction-in vitro ChIP-
qPCR assay using HeLa nuclear extract as the HAT re-
source instead of recombinant P300. The nuclear extract 
containing not only P300/CBP but also other HATs and 
HDACs, provided a cell-like environment than that ob-
served with only recombinant P300. Although the basal 
level of acetylation without Bi-PIP1 increased, Bi-PIP1 en-
hanced acetylation of Nuc1 but not Nuc2 (Supplementary 
Figure 7), suggesting the possibility of applying Bi-PIPs to 
living cells. 
A bottleneck in the utility of Bi-PIPs is the potential of Bi 
to impair the natural function of P300/CBP such as the 
propagation of histone acetylation inside the living cells. In 
this regard, we evaluated the effect of increasing amount 
of Bi on the BD-mediated histone acetylation. Interestingly, 
even a ten-fold higher concentration of Bi than that of Bi-
PIP1 did not affect the BD-mediated acetylation induced by 
Bi-PIP1 (Supplementary Figure 8).  It is reasonable to as-
sume that the binding of BD and Bi could be in equilibrium, 
which provides the BD with the opportunity to interact 
with Bi-PIP1 even with the high doses of Bi. The rapid dis-
sociation of CBP30 from P300 further supports this no-
tion.30 
We then investigated the cellular activity of Bi-PIPs using 
the HEK293T cell line. The cell permeability of PIPs is 
known to vary depending on the chemical structures and 
cell lines.39,40 To ensure that all the compounds enter the 
cells, we used a delivery reagent, Endo-Porter.41 We found 
that the inclusion of Endo-Porter greatly improved cellular 
uptake of a fluorescent PIP whose permeability is poor 
without the reagent (Supplementary Figure 9). 
Considering the fundamental role of P300/CBP as the 
transcriptional coactivator to activate gene expression, we 
performed a transcriptome analysis of total RNA extracted 
from cells treated with the compounds. The criteria of >2 
or <−2 fold change and <0.05 P value was applied for de-
tecting differentially expressed transcripts. The Bi mono-
mer showed only a minimal change in gene expression (2 
upregulated transcripts and 4 downregulated transcripts). 
The PIP1 and PIP2 monomers caused a moderate change in 
global gene expression (32 up- and 31 downregulated by 
PIP1, and 143 up- and 63 downregulated by PIP2). On the 
other hand, Bi-PIP1 and Bi-PIP2 conjugates gave greater 
transcriptome changes, mainly for activation, rather than 
repression (473 up- and 258 downregulated by Bi-PIP1, and 
446 up- and 137 downregulated by Bi-PIP2, Supplemen-
tary Figure 10). The results, therefore, reflect the recruit-
ment of P300/CBP onto the chromatin by Bi-PIPs, which 
cannot occur by Bi monomer or PIP monomers. 
We then evaluated if the difference in DNA sequence-se-
lectivity could cause a dissimilar change in gene expression. 
In contrast to the in vitro ChIP assay shown above, genes 
activated by the two Bi-PIPs were not exclusive, and 247 
transcripts were commonly upregulated by both Bi-PIP1 
and Bi-PIP2 (Supplementary Figure 11). This is reasona-
ble because the binding sites of Bi-PIP1 and Bi-PIP2 are not 
exclusively distributed throughout the genome; thus, some 
genes could be activated by both Bi-PIP1 and Bi-PIP2. To 
check whether the sequence-selective activity attributes to 
the the cellular function of Bi-PIPs, ChIP-sequencing 
(ChIP-seq) was performed using the antibody for pan-acet-
ylated H3. Mapped reads were processed by One-stage DIf-
fereNtial peak caller (ODIN)42 to detect differential peaks 
between Bi-PIP1 and Bi-PIP2-treated cells. Analysis of the 
target sequences in the region of differential peaks re-
vealed that the target sequence of Bi-PIP1 appeared more 
frequently in the loci where Bi-PIP1 showed higher peak 
signal than that in Bi-PIP2 (Figure 4a, left). Conversely, 
the target sequence of Bi-PIP2 got enriched in the loci 
where Bi-PIP2 showed higher peak signal than that in Bi-
PIP1 (Figure 4a, right). The enrichment of the target se-
quence for Bi-PIP1 was relatively lower than that for Bi-
PIP2, which could be attributed to the more extensive se-
quence match sites for the Bi-PIP1 than Bi-PIP2 (8 fold in 
theory because it has three more W recognition). There-
fore, it is reasonable to assume that the Bi-PIP1 could dis-
tribute more broadly and the binding sequence might be 
often found in the differential peak region for Bi-PIP2. 
Taken together, the observed epigenome changes in acet-
ylation verifies the sequence-selective bioactivity of Bi-
PIPs. 
Although the result above showed that some genes were 
activated by both Bi-PIP1 and Bi-PIP2, differentially acti-
vated transcripts were also identified in the microarray 
data by applying criteria of >1.5 or <−1.5 fold change (Fig-
ure 4b, Supplementary Table 4, 5). Among these 
uniquely activated transcripts, the most upregulated pro-
tein-coding genes with Bi-PIP1 and Bi-PIP2 were NTS (neu-
rotensin) and IER5L (immediate early response 5-like), re-
spectively (Figure 4b, Supplementary Table 4, 5). We 
verified the expression of these two transcripts using RT-
qPCR (Figure 4c). To gain insights into the mechanism of 
activation, we searched for the target sequences of Bi-PIP1  
  
Figure 4. Bi-PIPs epigenetically activate selective gene expression inside living cells. (a) Motif search analysis. After ChIP-seq for 
acetylated H3, differential peaks between Bi-PIP1 and Bi-PIP2-treated cells were detected by ODIN. Each differential peak region 
was searched for the match sites of Bi-PIP1 (5′–WWCWGWCW–3′, left) and Bi-PIP2 (5′–WGCCGCCW–3′, right). (b) Volcano plots 
of transcriptome comparison of Bi-PIP1 vs. vehicle (left) and Bi-PIP2 vs. vehicle (right). Uniquely upregulated transcripts by indi-
vidual Bi-PIP (>1.5 fold change) are indicated as colored dots. (c) Expression of NTS and IER5L was confirmed by RT-qPCR. Error 
bars represent standard deviation of data from two culture wells. (d) Genomic loci of NTS (upper) and IER5L (lower). Match sites 
for Bi-PIP1 (5′–WWCWGWCW–3′) and Bi-PIP2 (5′–WGCCGCCW–3′) are indicated as blue and red diamonds, respectively. 
(5′–WWCWGWCW–3′) and Bi-PIP2 (5′–WGCCGCCW–3′) 
in each gene locus. Interestingly, the genomic sequence of 
the NTS locus contains the binding sites for Bi-PIP1 but not 
for Bi-PIP2 (Figure 4d). Likewise, the IER5L locus pos-
sesses the binding sites for Bi-PIP2 but not for Bi-PIP1 (Fig-
ure 4d). Furthermore, the differential peak analysis of 
ChIP-seq data between each Bi-PIP and vehicle-treated 
cells revealed that the acetylation at IER5L locus increased 
upon the Bi-PIP2 treatment and was detected as significant 
peaks by ODIN (Supplementary Figure 12). On the other 
hand, ODIN did not detect substantial peaks in the NTS 
locus. However, there was a notable change in the shape of 
the peak in the data (Supplementary Figure 12). This ob-
servation possibly reflects the chromatin remodeling or 
nucleosome eviction after Bi-PIP1 induced acetylation at 
the locus. These results suggest that NTS and IER5L are pu-
tative target genes of Bi-PIP1 and Bi-PIP2, respectively. 
 
■ DISCUSSION 
Acetylated histones function by neutralizing the positive 
charge of lysine to loosen the chromatin structure, and by 
being recognized by BD-containing proteins. BD-
containing proteins are diverse nuclear proteins including 
HATs, histone methyltransferases, and ATP-dependent 
chromatin remodeling complexes.43 Recruiting these pro-
teins at acetyl lysine sites thus contributes to gene activa-
tion by remodeling chromatin,44 introducing methylation 
at lysine 4 in histone H3 (H3K4me), or introducing de novo 
acetylation near the site. In this study, we sought to take 
advantage of the BD-mediated natural propagation system 
of histone acetylation for the control of targeted acetyla-
tion. With the reliable and robust molecular design, we 
successfully developed ‘Bi-PIP,’ which recruits P300/CBP 
to selective DNA sequences. Based on biochemical assays, 
Bi-PIP-mediated histone acetylation at target DNA se-
quences was demonstrated as a proof-of-concept of the 
molecular mechanism. Moreover, cellular experiments 
showed the sequence-selective histone acetylation and 
transcriptional activation in endogenous genome by Bi-
PIPs, indicating their applicability in living cells. 
Recently Ansari’s group reported a conjugate called Syn-
TEF by coupling a PIP with another bromodomain inhibi-
tor (+)-JQ1, selective to the bromodomain and extratermi-
nal (BET) protein family.45 Syn-TEF1 targeting expanded 
GAA repeats in the frataxin (FXN) gene successfully re-
cruited BET protein BRD4 (bromodomain 4) to the gene 
locus in Friedreich’s ataxia (FRDA) patient-derived cells, 
resulting in transcriptional elongation of FXN. However, 
Syn-TEF and Bi-PIP target different members of the BD 
protein family, and therefore is demonstrated to cause dif-
ferent outcomes i.e., while Syn-TEF causes BRD4-
dependent transcriptional elongation, Bi-PIP causes P300-
dependent histone acetylation. Thus, Bi-PIP and Syn-TEF 
can be used for different purposes and this make to expand 
the range of potential applications of the synthetic epige-
netic regulators. 
Despite the successful demonstration of the potential of 
Bi-PIP as biomimetic artificial epigenetic code, there is still 
 a need to improve the sequence-selective capacity of the 
Bi-PIPs inside the living cells. The reason is that the ChIP-
seq analysis of the Bi-PIP-treated cells implied that the 
acetylated loci by each Bi-PIP could contain not only its 
target sequences but also the other possible binding sites. 
Also, the microarray studies suggested that although some 
genes were selectively activated by each Bi-PIP, others 
were activated by both Bi-PIPs.  The modest selectivity of 
the current version of Bi-PIPs could be attributed to the 
non-exclusive distribution of the two target sequences on 
the genome-wide scale. Nevertheless, the next-generation 
Bi-PIPs with extended recognition capacity46 or those that 
are designed to have a cooperative binding effect47 could 
target the longer DNA sequences and overcome the non-
selective outcome. Furthermore, a comprehensive evalua-
tion of the binding affinity could facilitate the design of ad-
vanced Bi-PIPs with better specificity towards the loci of 
interest.48 Besides, the designer PIPs can also have an alter-
nate application as the guiding factor for the BD inhibitor 
to target multiple short sequence motifs in the genome and 
epigenetically activate the desired gene network.49 
So far, we have developed a variety of PIP-based se-
quence-selective epigenetic regulators by employing small 
molecules that modulate epigenetic writers or erasers, in-
cluding HDAC inhibitor (SAHA),8 HAT activator (CTB),16 
and HAT inhibitor (C646).50 In this study, we expanded the 
utility of PIP-based sequence-selective epigenetic regula-
tors to target epigenetic readers. Given that histone codes 
fundamentally function by being recognized by epigenetic 
readers, sequence-selective inhibitors of epigenetic readers 
such as Bi-PIP work as readable artificial histone codes 
while operating similarly as the natural ones. In the future, 
other inhibitors of epigenetic readers will also be employed 
to achieve diverse outcomes such as the introduction of 
other histone PTMs, removing histone PTMs, and chroma-
tin remodeling. 
 
■ EXPERIMENTAL SECTION 
All experimental procedures are provided in the Support-
ing Information. 
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